Get the Stockscreener App
1.35
6.30%
0.08
After Hours:
1.35
Oncolytics Biotech Inc stock is traded at $1.35, with a volume of 1.56M.
It is up +6.30% in the last 24 hours and up +25.00% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.27
Open:
$1.3
24h Volume:
1.56M
Relative Volume:
1.33
Market Cap:
$135.49M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-5.104
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
+3.05%
1M Performance:
+25.00%
6M Performance:
+115.83%
1Y Performance:
+40.82%
1-Day Range:
$1.27
$1.38
1-Week Range:
$1.20
$1.38
52-Week Range:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.35 | 128.58M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 3.1%Here's What Happened - MarketBeat
Market Recap: Is Oncolytics Biotech Inc likely to announce a buybackIndex Update & Free Accurate Trade Setup Notifications - خودرو بانک
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - Cantech Letter
Oncology Investment Surge Hits $1.3B as Private Sector Fills Public Funding Gaps - Baystreet.ca
Oncolytics Biotech Expands GOBLET Study to U.S., Shows Promising Results - TipRanks
Oncolytics Biotech Inc - Menafn.com
Profit Review: How sensitive is Oncolytics Biotech Inc to inflationJuly 2025 Rallies & Precise Buy Zone Identification - خودرو بانک
Stock Analysis: What is the long term forecast for Gamblingcom Group Limited stockWeekly Volume Report & Daily Profit Maximizing Tips - خودرو بانک
Oncolytics Biotech® Provides Update On GOBLET Study Progress And U.S. Site Expansion - Barchart.com
Panic Selling: What is ESRTs valuation compared to sectorMarket Activity Report & Community Trade Idea Sharing Platform - خودرو بانک
Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference - ACCESS Newswire
Fed Watch: What’s the RSI of Oncolytics Biotech Inc. stockMarket Rally & Community Verified Trade Signals - خودرو بانک
Resistance Check: What are the future prospects of Oncolytics Biotech IncPortfolio Return Summary & Advanced Technical Analysis Signals - خودرو بانک
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Published on: 2025-09-15 14:55:02 - خودرو بانک
Oncolytics Biotech (TSE:ONC) Share Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Profit Recap: Will DLNGPRB stock benefit from M AEarnings Growth Report & Community Supported Trade Ideas - خودرو بانک
Can a trend reversal in Oncolytics Biotech Inc. lead to recoveryJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Will Oncolytics Biotech's (ONCY) Upcoming CEO Presentation Reinforce Management Credibility Among Investors? - simplywall.st
FDA Accelerates Cancer Drug Pipeline as Market Momentum Surges Past $400B - Baystreet.ca
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market - The Malaysian Reserve
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions - Cantech Letter
Premarket Movers: RAPP, MCRB, JAGX. MEIP… - RTTNews
Oncolytics Biotech Reports Promising Results in Metastatic Colorectal Cancer Studies - TipRanks
Is Oncolytics Biotech Inc. a speculative investmentNew Guidance & High Accuracy Swing Entry Alerts - خودرو بانک
What’s next for Oncolytics Biotech Inc. stockEarnings Recap Report & Stepwise Swing Trade Plans - خودرو بانک
What is Oncolytics Biotech Inc.’s TAM (Total Addressable Market)Weekly Investment Summary & Weekly High Return Forecasts - خودرو بانک
Multi asset correlation models including Oncolytics Biotech Inc.2025 Top Gainers & High Accuracy Buy Signal Tips - Newser
Will Oncolytics Biotech Inc. stock recover after recent dropBond Market & Fast Entry and Exit Trade Plans - Newser
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
Technical signs of recovery in Oncolytics Biotech Inc.2025 Macro Impact & Reliable Volume Spike Trade Alerts - Newser
Chart overlay techniques for tracking Oncolytics Biotech Inc.Trade Analysis Report & Low Drawdown Investment Strategies - Newser
Does Oncolytics Biotech Inc. meet Warren Buffett’s criteriaWeekly Market Summary & Daily Entry Point Trade Alerts - خودرو بانک
How to manage a losing position in Oncolytics Biotech Inc.Quarterly Portfolio Report & Real-Time Volume Analysis - Newser
Does Oncolytics Biotech Inc. show high probability of reboundEarnings Growth Report & Entry Point Strategy Guides - Newser
Leading vs lagging indicators on Oncolytics Biotech Inc. performance2025 Trade Ideas & AI Based Buy/Sell Signal Reports - Newser
How to forecast Oncolytics Biotech Inc. trends using time seriesQuarterly Earnings Report & Consistent Profit Trading Strategies - Newser
Can Oncolytics Biotech Inc. navigate macro headwindsWeekly Loss Report & Daily Risk Controlled Trade Plans - خودرو بانک
Can swing trading help recover from Oncolytics Biotech Inc. lossesMarket Volume Report & Safe Entry Point Alerts - Newser
Can Oncolytics Biotech Inc. reach all time highs this yearGlobal Markets & Momentum Based Trading Ideas - خودرو بانک
Is Oncolytics Biotech Inc. likely to announce a buybackAnalyst Downgrade & Safe Capital Growth Trade Ideas - خودرو بانک
Is Oncolytics Biotech Inc. still worth holding after the dip2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
Oncolytics Biotech Inc. stock retracement – recovery analysisTrade Ideas & Verified Technical Signals - Newser
Applying big data sentiment scoring on Oncolytics Biotech Inc.Market Sentiment Summary & High Conviction Buy Zone Picks - Newser
Quantitative breakdown of Oncolytics Biotech Inc. recent moveWeekly Profit Report & Fast Gaining Stock Reports - Newser
Can momentum traders help lift Oncolytics Biotech Inc.July 2025 Outlook & Fast Entry High Yield Tips - Newser
Can Oncolytics Biotech Inc. stock outperform in a bear marketPortfolio Growth Summary & High Win Rate Trade Tips - خودرو بانک
How to use a screener to detect Oncolytics Biotech Inc. breakoutsMarket Growth Summary & Fast Gain Swing Trade Alerts - Newser
Cellectar Biosciences shares fall 1.24% premarket as Oncolytics Biotech Inc. gains FDA approval for breakthrough therapies. - AInvest
How hedge fund analytics apply to Oncolytics Biotech Inc. stock2025 Valuation Update & Advanced Technical Analysis Signals - Newser
What’s the recovery path for long term holders of Oncolytics Biotech Inc.Earnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):